Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis

Cancers

ZacharyS. Rosh¹  KeikoM. Kang¹  Leonora Balaj¹  Koushik Muralidharan¹  JuliaL. Small¹  Anudeep Yekula¹  BobS. Carter¹  PamelaS. Jones¹ 

[1] Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA;

关键词: brain tumor;    glioma;    brain tumor metastasis;    melanoma;    liquid biopsy;    cfDNA (cell free DNA);   

DOI  :  10.3390/cancers13061227

来源: DOAJ

【 摘 要 】

Liquid biopsy provides a minimally invasive platform for the detection of tumor-derived information, including hotspot mutations, such as BRAF V600E. In this study, we provide evidence of the technical development of a ddPCR assay for the detection of BRAF V600E mutations in the plasma of patients with glioma or brain metastasis. In a small patient cohort (n = 9, n = 5 BRAF V600E, n = 4 BRAF WT, n = 4 healthy control), we were able to detect the BRAF V600E mutation in the plasma of 4/5 patients with BRAF V600E-tissue confirmed mutant tumors, and none of the BRAF WT tumors. We also provide evidence in two metastatic patients with longitudinal monitoring, where the plasma-based BRAF V600E mutation correlated with clinical disease status. This proof of principle study demonstrates the potential of this assay to serve as an adjunctive tool for the detection, monitoring, and molecular characterization of BRAF mutant gliomas and brain metastasis.

【 授权许可】

Unknown